The field of cellular immunotherapy has undergone a profound transformation in recent years, with autologous chimeric antigen receptor (CAR) T-cell therapies emerging as the standard-of-care option ...

Over the past decade, several novel immunotherapies have transformed the treatment landscape of relapsed or refractory B-cell acute lymphoblastic leukaemia. In the pivotal TOWER trial, blinatumomab—a ...